SEARCH:
Print

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, May 1, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 

1.

Details of the person discharging managerial responsibilities/person   closely associated  

a)

Name

Laurence de Moerlooze

2.

Reason for the notification

a)

Position/status

 

Executive Vice   President and Chief Medical Officer of Bavarian Nordic A/S

b)

Initial notification/Amendment

Initial   notification

3.

Details of the issuer, emission allowance market participant, auction   platform, auctioneer or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s): section to be repeated for (i) each type   of instrument; (ii) each type of transaction; (iii) each date; and (iv) each   place where transactions have been conducted

a)

Description of the financial instrument, type of instrument
 
 

Identification code

Restricted   Stock Units


 
  DK0015998017

b)

Nature of the transaction

Grant

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 

 

DKK 149.28

12,976

d)

Aggregated   information

-           Aggregated volume

-           Price

 

12,976

DKK 1,937,057.28

e)

Date of the transaction

2020-05-01

f)

Place of the transaction

Outside a   trading venue

 

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 

Company Announcement no. 27 / 2020

Published on May 01, 2020, 15:23 CET